“Current evidence points to an effective pneumococcal vaccine that could begin to save lives now. We cannot afford to wait until another million children die next year. We must act now.”

Adenike Grange

President of the International Pediatric Association

High-risk infants and children, including those with HIV infection, can be safely and effectively vaccinated with pneumococcal conjugate vaccines

High-risk infants and children, including those with HIV, can be safely and effectively vaccinated with pneumococcal conjugate vaccines

South Africa

South Africa: Life-Saving Potential for HIV-Positive Children

Two vaccine efficacy studies in Africa with the 9-valent pneumococcal conjugate vaccine in The Gambia and South Africa demonstrate that multi-valent pneumococcal conjugate vaccines are safe and effective even for HIV-positive children and have the potential to make a major health impact especially in rural settings where access to treatment is limited.

In Soweto, South Africa, a 9-valent pneumococcal vaccine trial demonstrated that the vaccine can protect HIV infected children from serious, antibiotic resistant cases of pneumococcal disease and has the potential to make a major health impact. The vaccine was 83% effective in non HIV-infected children and 65% effective in HIV-infected children. The vaccine also significantly reduced antibiotic-resistant cases of invasive pneumococcal disease.